HER2CLIMB: Phase II Study of Tucatinib Plus Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer

December 10-14, 2019; San Antonio, Texas
In patients with HER2+ MBC and previous treatment with trastuzumab, pertuzumab, and T-DM1, tucatinib in combination with trastuzumab and capecitabine substantially extended survival outcomes compared with trastuzumab and capecitabine alone, including in patients with brain metastases.
Format: Microsoft PowerPoint (.ppt)
File Size: 306 KB
Released: December 16, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.
Puma Biotechnology
Seattle Genetics

Related Content

Expert-authored commentary on strategies for rethinking breast cancer clinical trial practices during the COVID-19 pandemic from Clinical Care Options (CCO)

Hope S. Rugo, MD Released: September 28, 2020

Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic

Hope S. Rugo, MD Released: September 25, 2020

Downloadable summary slides with quick expert analysis of the optimal management of patients with HER2-positive metastatic breast cancer, from Clinical Care Options.

Sara Hurvitz, MD, FACP Sara Tolaney, MD, MPH Released: September 23, 2020

Read this commentary from Clinical Care Options to gain expert perspectives on PARP inhibition in early, metastatic, and triple-negative breast cancer.

Mark E. Robson, MD Released: September 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.